Premium
Dysregulated expression of transforming growth factor β and its type‐I and type‐II receptors in basal‐cell carcinoma
Author(s) -
Furue Masutaka,
Kato Mitsuyasu,
Nakamura Koichiro,
Nashiro Kiyoko,
Kikuchi Kanako,
Okochi Hitoshi,
Miyazono Kohei,
Tamaki Kunihiko
Publication year - 1997
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19970516)71:4<505::aid-ijc1>3.0.co;2-y
Subject(s) - transforming growth factor , basal cell carcinoma , biology , stromal cell , seborrheic keratosis , epidermis (zoology) , stroma , basal (medicine) , receptor , pathology , endocrinology , medicine , cancer research , immunohistochemistry , basal cell , anatomy , immunology , biochemistry , genetics , insulin
In mammals, transforming growth factor‐β (TGF‐β) is found in 3 highly homologous isoforms that exert their effects via heteromeric complexes of type‐I and type‐II receptors (TβR‐I and TβR‐II). TGF‐β regulates the growth and metabolism of various cell types, including keratinocytes. We have investigated the immunohistological localization of TGF‐β1, TGF‐β2, TβR‐I and TβR‐II in normal human skin, basal‐cell carcinoma (BCC), Bowen's disease, seborrheic keratosis, eccrine poroma and eccrine spiradenoma using frozen tissue specimens. In normal human skin, the immunoreactive TGF‐β2, but not TGF‐β1, was detected predominantly in the epidermis, follicles and sebaceous glands. The epidermal expression of TβR‐I and TβR‐II was very weak in the majority of normal skins. In BCC, TGF‐β2 expression was markedly reduced or completely negative. In addition, TβR‐I‐ and TβR‐II‐positive stromal cells were accumulated in the fibrotic stroma in some BCCs. These stromal cells were partly but moderately positive for TGF‐β1. Decreased expression of TGF‐β2 was likely to be associated with the differentiation state of BCC cells, since TGF‐β2 expression was clearly observed in the squamoid foci of BCC. In addition, no expression of TGF‐β2 was detected in the eccrine secretory portion or in eccrine spiradenoma, but it was detected in the upper eccrine ducts and in eccrine poroma. Int. J. Cancer 71:505‐509, 1997. © 1997 Wiley‐Liss, Inc.